Study wrapper · #498
Medical Treatment of Female Sexual Dysfunction.
Editor's note
This clinical review of the medical management of female sexual dysfunction identifies bremelanotide, which is PT-141, as one of two psychoactive agents indicated for generalised acquired hypoactive sexual desire disorder in premenopausal women, alongside flibanserin. PT-141 is a melanocortin-receptor agonist. The review frames FSD within a biopsychosocial model and a multidisciplinary, stepwise approach, positioning drug therapy as one component rather than a standalone answer. As a narrative review it consolidates guidance rather than presenting new trial data, and it does not detail comparative efficacy or safety magnitudes. For PT-141 readers, the value is authoritative placement: the peptide is recognised for a specific, defined indication in a specific population, which helps calibrate where it fits among options.
Plain-language abstract
This review explains the medical options for treating female sexual dysfunction. It identifies bremelanotide, also known as PT-141, as one of two medicines approved for a specific type of low sexual desire in premenopausal women, alongside flibanserin, while noting that hormone therapy is used mainly around menopause. The authors emphasise a whole-person approach that combines counselling and medical care rather than relying on drugs alone. For readers interested in PT-141, the article confirms it has a defined, approved role for a particular group of women. It summarises existing guidance rather than reporting a new study, so it helps show where the peptide fits among treatments.